Edition:
United States

Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

11.37USD
18 May 2018
Change (% chg)

$-0.08 (-0.70%)
Prev Close
$11.45
Open
$11.66
Day's High
$11.85
Day's Low
$11.29
Volume
287,086
Avg. Vol
139,518
52-wk High
$29.02
52-wk Low
$11.05

Latest Key Developments (Source: Significant Developments)

Jounce Therapeutics Q4 Loss Per Share $0.29
Thursday, 8 Mar 2018 06:30am EST 

March 8 (Reuters) - Jounce Therapeutics Inc ::JOUNCE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.29.COLLABORATION REVENUE WAS $13.0 MILLION FOR Q4 OF 2017, COMPARED TO $20.3 MILLION.JOUNCE THERAPEUTICS - EXPECTS CASH BURN ON OPERATING EXPENSES AND CAPITAL EXPENDITURES FOR FULL YEAR 2018 TO BE APPROXIMATELY $80.0 MILLION TO $100.0 MILLION.EXPECTS TO RECORD APPROXIMATELY $50.0 MILLION TO $60.0 MILLION IN COLLABORATION REVENUE IN 2018.JOUNCE THERAPEUTICS - SEES EXISTING CASH, CASH EQUIVALENTS FUNDING OPERATING EXPENSES & CAPITAL EXPENDITURE REQUIREMENTS FOR AT LEAST NEXT 24 MONTHS.  Full Article

Jounce Therapeutics reports Q3 loss $0.13/shr
Monday, 13 Nov 2017 06:30am EST 

Nov 13 (Reuters) - Jounce Therapeutics Inc :Jounce Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.13.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Jounce Therapeutics Inc- ‍remain on track to announce preliminary efficacy data for phase 1/2 iconic study in 1H 2018​.Jounce Therapeutics Inc - ‍jounce has narrowed its financial guidance previously provided for full year 2017​.Jounce Therapeutics Inc- ‍now expects to use approximately $100.0 million to $110.0 million in cash for full year 2017​.Jounce Therapeutics Inc- ‍collaboration revenue was $18.1 million for Q3 of 2017, compared to $16.9 million for same period in 2016​.Jounce Therapeutics Inc- ‍as of Sept 30, 2017, cash, cash equivalents and investments were $283.4 million, compared to $257.4 million as of Dec 31, 2016​.Jounce Therapeutics - now expects collaboration revenue from non-cash amortization of Celgene upfront payment​ for FY 2017 to be $70 million to $75 million.  Full Article

Jounce Therapeutics qtrly loss per share $0.02
Tuesday, 9 May 2017 08:00am EDT 

May 9 (Reuters) - Jounce Therapeutics Inc :Jounce therapeutics reports first quarter 2017 financial results.Jounce therapeutics inc qtrly loss per share $0.02.Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.Jounce therapeutics inc - cash, cash equivalents and investments as of march 31, 2017 were $340.0 million, compared to $257.4 million as of december 31, 2016.Jounce therapeutics inc - reiterates financial guidance previously provided for full year 2017.  Full Article

Jounce Therapeutics Q4 earnings per share $0.05
Friday, 10 Mar 2017 08:00am EST 

Jounce Therapeutics Inc : Jounce Therapeutics reports fourth quarter and full year 2016 financial results . Q4 earnings per share $0.05 . Q4 earnings per share view $0.04 -- Thomson Reuters I/B/E/S . Qtrly collaboration revenue $20.3 million versus nil revenue last year . Jounce Therapeutics Inc - expects to use approximately $100.0 to $120.0 million in cash for full year 2017 .Jounce Therapeutics Inc - expects collaboration revenue for full year 2017 of approximately $80.0 million representing amortization of Celgene upfront payment of $225.0 million received in 2016.  Full Article

Jounce Therapeutics announces pricing of initial public offering
Thursday, 26 Jan 2017 09:27pm EST 

Jounce Therapeutics Inc : Announces pricing of initial public offering .says pricing of its initial public offering of 6.3 million shares of common stock at a public offering price of $16.00 per share.  Full Article

BRIEF-Jounce Therapeutics Q1 Shr Loss $0.40

* JOUNCE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS